Midpregnancy and cord blood immunologic biomarkers, HLA genotype, and pediatric celiac disease - 27/09/17
![](/templates/common/images/mail.png)
The Norwegian Mother and Child Cohort Study (MoBa) was supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research, National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS) (contract no. N01-ES-75558), NIH/National Institute of Neurological Disorders and Stroke (NINDS) (grant no. 1 UO1 NS 047537-01 and grant no. 2 UO1 NS 047537-06A1). This subproject within MoBa is supported by the Norwegian Research Council (grant no. 221909/F20). The genotyping service for this study was financed by Helse Sør-Øst. K.S. was funded through an unrestricted grant from Oak Foundation, Geneva, Switzerland. The funding sources did not influence the design, conduct, and reporting of the present study. |
|
Disclosure of potential conflict of interest: O. Midttun is an employee at Bevital, which carried out the analyses on cord blood. P. M. Ueland is a member of the steering board of the nonprofit Foundation to Promote Research into Functional Vitamin B12 Deficiency, which owns Bevital. J. P. Berg receives payment for lectures from MSD and Boehringer Ingelheim. L. C. Stene receives grant support from the Research Council of Norway. K. Størdal receives grant support from Oak Foundation, Geneva. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 139 - N° 5
P. 1696-1698 - mai 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?